Abstract
We have recently revealed that the new SARS-CoV-2 Omicron sublineages BA.4 and BA.5 exhibit increased resistance to cilgavimab, a therapeutic monoclonal antibody, and the resistance to cilgavimab is attributed to the spike L452R substitution. However, it remains unclear how the spike L452R substitution renders resistance to cilgavimab. Here, we demonstrated that the increased resistance to cilgavimab of the spike L452R is possibly caused by the steric hindrance between cilgavimab and its binding interface on the spike. Our results suggest the importance of developing therapeutic antibodies that target SARS-CoV-2 variants harboring the spike L452R substitution.
Funding Information
  • Japan Agency for Medical Research and Development (20fk0108146, 21fk0108494)
  • AMED Research Program on HIV/AIDS (21fk0410039)
  • JST CREST JPMJCR20H4
  • JSPS Core-to-Core Program (JPJSCCA20190008)
  • the Tokyo Biochemical Research Foundation

This publication has 16 references indexed in Scilit: